Serum levels of adipocyte fatty acid‐binding protein (AFABP) are increased in chronic haemodialysis (CD)

Sommer, Grit; Ziegelmeier, Michaela; Bachmann, Anette; Kralisch, Susan; Lössner, Ulrike; Kratzsch, Jürgen; Blüher, Matthias; Stümvoll, Michael; Faßhauer, Mathias

doi:10.1111/j.1365-2265.2008.03277.x

Cited by 33 publications

(27 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in accordance with previous data from our group showing that serum creatinine and AFABP are independently associated in preeclampsia (27). Furthermore, we have recently demonstrated that AFABP is more than ten-fold higher in patients on chronic hemodialysis as compared with controls (30). These results further support the notion that renal elimination is a major route by which physiological AFABP serum levels are maintained.…”

Section: Discussionsupporting

confidence: 93%

“…Furthermore, AFABP concentrations are significantly associated with BMI before and 6 months after gastric banding in 33 morbidly obese patients (29). In addition, we have recently shown that BMI is independently correlated with circulating AFABP in patients on chronic hemodialysis (30). Taking this published evidence into consideration, circulating AFABP appears to be regulated in a body weightdependent manner similar to the adipokine leptin.…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus

Kralisch

Stepan²,

Kratzsch³

et al. 2009

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Objective: Adipocyte fatty acid binding protein (AFABP) was recently introduced as a novel adipokine, serum levels of which independently correlate with the development of the metabolic syndrome and cardiovascular disease in humans. In the current study, we investigated serum concentrations of AFABP in patients with gestational diabetes mellitus (GDM) as compared with healthy pregnant controls matched for gestational age and fasting insulin. Design and methods: AFABP was determined by ELISA in controls (nZ80) and GDM patients (nZ40) and correlated to clinical and biochemical measures of renal function, glucose and lipid metabolism, as well as inflammation, in both groups. Results: Median serum AFABP concentrations were significantly elevated in subjects with GDM (22.9 mg/l) as compared with healthy pregnant controls (18.3 mg/l; P!0.05). Furthermore, GDM was independently associated with AFABP concentrations in multiple regression analysis (P!0.05). In addition, markers of adiposity (body mass index, serum leptin), triglycerides and serum creatinine were independently associated with circulating AFABP (P!0.05). Conclusions: Maternal AFABP concentrations are significantly increased in GDM. The adipokine might contribute to the increased metabolic and cardiovascular risk of the disease.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 87%

Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus

Kralisch

Stepan²,

Kratzsch³

et al. 2009

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…These results are in accordance with the hypothesis that renal elimination is a route by which physiological chemerin serum levels are maintained, and they support recent findings from our group in a nonpregnant population on hemodialysis [19]. Furthermore, it is interesting to note in this context that we and others have recently suggested that renal elimination is a major mechanism influencing serum concentrations of various other adipokines including adiponectin [20], leptin [21], retinol-binding protein-4 [22], AFABP [23], and fibroblast growth factor-21 [24]. These results support the notion that markers of renal function should be included in studies concerning chemerin physiology.…”

Section: Discussionsupporting

confidence: 73%

Circulating Levels of the Adipokine Chemerin in Gestational Diabetes Mellitus

Pfau¹,

Stepan²,

Kratzsch

et al. 2010

Horm Res Paediatr

Self Cite

View full text Add to dashboard Cite

Background: Chemerin was recently introduced as a novel adipokine playing a crucial role in adipocyte differentiation and insulin signaling. In the current study, we investigated circulating chemerin levels in patients with gestational diabetes mellitus (GDM) as compared to healthy pregnant controls matched for gestational age and fasting insulin. Methods: Chemerin was quantified by ELISA in control (n = 80) and GDM (n = 40) patients and correlated to clinical and biochemical measures of renal function, glucose and lipid metabolism, as well as inflammation, in both groups. Results: Median maternal serum chemerin concentrations were not significantly different in subjects with GDM (230.3 µg/l) as compared to healthy pregnant controls (217.6 µg/l). Chemerin significantly and positively correlated with homeostasis model assessment of insulin resistance (HOMA-IR) and serum creatinine in uni- and multivariate analyses. Furthermore, chemerin serum levels were highest in patients in the third tertile of HOMA-IR. Conclusions: Chemerin is independently associated with markers of insulin resistance and renal dysfunction but is not dysregulated in GDM if patients are matched with controls for fasting insulin.

show abstract

“…These findings are in contrast to recent results indicating that other metabolic hormones, including several adipokines, show renal clearance. Thus, circulating levels of the adipokines leptin (12), adiponectin (13), retinol-binding protein-4 (14), zinc-a2-glycoprotein (15), adipocyte fatty acid-binding protein (16), fibroblast growth factor 21 (17), and chemerin (18) are significantly elevated in end-stage renal disease in contrast to the myokine irisin. It needs to be established in future experiments by which mechanisms circulating irisin is being eliminated.…”

Section: Discussionmentioning

confidence: 99%

Serum levels of the myokine irisin in relation to metabolic and renal function

Ebert

Focke

Petroff

et al. 2014

European Journal of Endocrinology

Self Cite

130

View full text Add to dashboard Cite

Objective: Irisin has recently been introduced as a novel myokine which reverses visceral obesity and improves glucose metabolism in mice. However, regulation of irisin in humans in relation to renal and metabolic disease has not been comprehensively studied. Design and methods: Serum irisin levels were quantified by ELISA and correlated with anthropometric and biochemical parameters of renal function, glucose and lipid metabolism, as well as inflammation, in 532 patients with stages 1-5 of chronic kidney disease (CKD). Results: Median serum irisin levels adjusted for age, gender, and BMI significantly decreased with increasing CKD stage and lowest concentrations were seen in patients with CKD stage 5. Furthermore, irisin concentrations were associated with facets of the metabolic syndrome including diastolic blood pressure, markers of impaired glucose tolerance, and dyslipidemia in univariate analysis. Moreover, markers of renal function, e.g. glomerular filtration rate, and insulin resistance, e.g. homeostasis model assessment of insulin resistance, remained independently associated with circulating irisin levels in robust multivariate analysis. Conclusions: We show that irisin serum concentrations decrease with increasing CKD stage and are independently and positively predicted by renal function and insulin resistance. The physiological relevance of our findings, as well as the factors contributing to irisin regulation in humans, needs to be further defined in future experiments.

show abstract

Serum levels of adipocyte fatty acid‐binding protein (AFABP) are increased in chronic haemodialysis (CD)

Abstract: Renal filtration appears as an important route of elimination of AFABP. Future studies should elucidate whether this adipocyte-expressed factor contributes to the increased risk of cardiovascular disease found in end-stage renal disease.

Cited by 33 publications

References 27 publications

Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus

Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus

Circulating Levels of the Adipokine Chemerin in Gestational Diabetes Mellitus

Serum levels of the myokine irisin in relation to metabolic and renal function

Contact Info

Product

Resources

About